« Return to News | Drug Sponsors

Fate Therapeutics names Christian Weyer president, CEO

Monday, October 15, 2012 11:44 AM

San Diego, Calif.-based Fate Therapeutics has appointed Christian Weyer, M.D., M.A.S., president and CEO, and elected him to the board of directors, effective immediately.

Previously, Dr. Weyer spent 12 years with Amylin Pharmaceuticals, most recently as senior vice president of R&D, until its acquisition by Bristol-Myers Squibb in August 2012.

William H. Rastetter, a partner at Venrock who has served as Fate's interim CEO since November 2011, will remain chairman of the board of directors.

"Fate Therapeutics is pioneering innovative strategies to harness the therapeutic potential of adult stem cell biology, targeting disease areas of high unmet need that have not been adequately addressed by other pharmaceutical modalities," said Dr. Weyer.  "I am excited to join Fate as we are well-poised to accelerate the advancement of key programs, including ProHema, which may enable a new treatment paradigm for patients undergoing hematopoietic stem cell transplantation."

At Amylin, Dr. Weyer contributed to the development, approval and commercialization of several first-in-class diabetes medicines.  Prior to Amylin, Dr. Weyer spent three years with the National Institutes of Health, NIDDK, in Phoenix, where he conducted clinical research on the pathogenesis of obesity and type 2 diabetes.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.